March 2025 clinical trial highlights
In the March 2025 clinical trial highlights, we'll showcase just a few of the many trials that are open for enrollment and seeking volunteers. To view more available trials for various forms of interstitial lung disease (ILD), please visit the 🔍 PFF Clinical Trial Finder.
Seeking participants with idiopathic pulmonary fibrosis
REVERT-IPF
- Study ID: NCT05671835
- Trial Phase: Phase 2
- Intervention: Oral drug
- Sponsor: Tvardi Therapeutics, Incorporated
- Study Contact: info@tvardi.com
Seeking lung transplant recipients
CLAD
- Study ID: NCT06476132
- Trial Phase: Phase 2
- Intervention: Oral drug
- Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Seeking participants with systemic sclerosis-associated interstitial lung disease
MOONSCAPE
- Study ID: NCT05785624
- Trial Phase: Phase 2
- Intervention: Subcutaneous (SC) injection
- Sponsor: Genentech, Inc.
- Study Contact: 888.662.6728; global-roche-genentech-trials@gene.com
Seeking participants with interstitial lung disease and idiopathic pulmonary fibrosis
129Xe MRI Cardiopulmonary
- Study ID: NCT06038630
- Trial Phase: Phase 2
- Intervention: 129Xe gas exchange MRI
- Sponsor: Bastiaan Driehuys, Duke University
- Study Contact: Bastiaan Driehuys, PhD (919.684.7786; bastiaan.driehuys@duke.edu)
Research updates
Watch the PFF CTI February Webinar Series
The PFF hosted its first webinar in the PFF CTI Webinar Series on Wednesday, February 19, 2025. You can now watch the recording to hear from people leading trials in pulmonary fibrosis (PF) and ILD and learn more about studies that are currently recruiting, including the REVERT-IPF study featured above.
Phase 2 idiopathic pulmonary fibrosis (IPF) study discontinued
Earlier this month, Pliant Therapeutics announced the discontinuation of its phase 2 IPF study, BEACON-IPF. BEACON-IPF was studying the efficacy and safety of the oral drug bexotegrast. The trial was stopped because there were more IPF-related adverse events in the treatment group, people receiving bexotegrast, compared to the placebo group. Early results showed that the treatment might help improve forced vital capacity (FVC).
A placebo looks like medicine but has no active ingredients in it. FVC is the measurement obtained when a patient completes a spirometry test (e.g., pulmonary function test).
Pliant Therapeutics plans to analyze the complete data from the BEACON-IPF trial and evaluate next steps for bexotegrast’s development.
This unfortunate update from the BEACON-IPF trial reinforces the urgent need for additional clinical trials to test the safety and effectiveness of potential new treatments and the importance of patient participation in those clinical trials. If you are enrolled in a BEACON-IPF trial and have questions, please contact the research coordinator or study doctor at your study site.
An early end to a clinical trial can cause strong emotions
Clinical trials are research studies that explore whether a drug, treatment, device, or medical strategy is safe and effective for humans. These studies follow strict scientific standards to protect patients and produce reliable research results.
Clinical trials follow the study protocol, a detailed plan like a playbook, for how the study will be carried out including how long the clinical trial is anticipated to last. An early or unexpected end to a clinical trial can be disappointing. However, researchers can still collect critical information even if the results aren’t positive. This is an essential part of the scientific discovery process and contributes toward the broader body of PF research.
To learn more about clinical trials, you can read the PFF clinical trial guide. If you are looking for additional support or resources about clinical trials, you can connect with the PFF Help Center by calling 844.TalkPFF (844.825.5733) or emailing help@pulmonaryfibrosis.org.